Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?

L. Bodei (Lisa), Bergsland, E.K. (Emily K.), de Herder, W.K. (Wouter K.), D. Ferone (Diego), Hicks, R.J. (Rodney J.), Hope, T.A. (Thomas A.), Kunikowska, J.A. (Jolanta A.), M. Pavel (Marianne), Reidy-Lagunes, D.L. (Diane L.), Siveke, J. (Jens), et al. Herrmann, K. (Ken)

2020-06-23

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Additional Metadata
Keywords	177Lu-DOTATATE, 90Y-DOTATOC, COVID-19, Infectious Disease, Lymphopenia, Neuroendocrine, PRRT, Radionuclide Therapy
Persistent URL	doi.org/10.2967/jnumed.120.249136, hdl.handle.net/1765/128222
Journal	Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Bodei, L., Bergsland, E.K. (Emily K.), de Herder, W.K. (Wouter K.), Ferone, D., Hicks, R.J. (Rodney J.), Hope, T.A. (Thomas A.), … Herrmann, K. (Ken). (2020). Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. doi:10.2967/jnumed.120.249136

Publication